FDA Approves the Immunotherapy Keytruda for Head and Neck CancerAugust 10th 2016
The immunotherapy pembrolizumab (Keytruda) has been granted an accelerated approval from the FDA for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease progresses after platinum-based chemotherapy.
Immunotherapy and Allogeneic HSCT: Unleashing Your Patient's Immune System SafelyJuly 21st 2016
Our immune system’s successful detection and destruction of abnormal cells is the hallmark of our body’s ability to either stop a malignancy from occurring or halt it once it has begun.
Michael A. Postow Discusses Nurses' Role in Treating Patients Receiving ImmunotherapiesApril 22nd 2016
Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses nurses’ roles in treating patients receiving immunotherapy, especially combination checkpoint blockades, which are typically associated with higher risks of adverse events.